HER2-positive Advanced Solid Tumors Clinical Trial
Official title:
A Multi-center, Single-arm, Phase І Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
This is a study of DP303c in patients with HER2-positive advanced solid tumors.
This is a multi-center, single-arm Phase I study to evaluate the pharmacokinetic profile, safety, and initial efficacy of DP303c in patients with HER2-positive advanced solid tumors. Patients will be treated with DP303c injection at 3.0 mg/kg every 3 weeks. Patients will receive DP303c until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05245058 -
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT03219268 -
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
|
Phase 1 |